Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VNK-101
- Development stage
- Unknown
- Lead developer
- Vycellix
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
VNK-101 is an allogeneic, off-the-shelf natural killer (NK) cell therapy being developed by Vycellix for the treatment of relapsed or refractory multiple myeloma. The therapy is engineered using Vycellix's proprietary VY-UC universal cell engineering platform, which utilizes a single-step CD45 engager strategy. This approach is designed to prevent the host immune system from rapidly eliminating the donor-derived cells, thereby addressing a significant barrier to the efficacy and persistence of allogeneic cell medicines. VNK-101 is currently in early-stage development, with the company preparing for Phase 1 clinical trials and regulatory interactions with the Swedish Medical Products Agency.
Beyond the preview
Go deeper on VNK-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VNK-101.